Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer

Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer

Abstract Background Acquired resistance to trastuzumab is a major clinical problem in the treatment of HER2-positive (HER2+) breast cancer patients. The selection of trastuzumab-resistant patients is a great challenge of precision oncology. The aim of this study was to identify novel epigenetic biom...

Full description

Bibliographic Details
Main Authors: Sònia Palomeras, Ángel Diaz-Lagares, Gemma Viñas, Fernando Setien, Humberto J. Ferreira, Glòria Oliveras, Ana B. Crujeiras, Alejandro Hernández, David H. Lum, Alana L. Welm, Manel Esteller, Teresa Puig
Format: Article
Language:English
Published: BMC 2019-07-01
Series:Breast Cancer Research
Subjects:
HER2+ breast cancer
Trastuzumab resistance
DNA methylation
TGFBI
Online Access:http://link.springer.com/article/10.1186/s13058-019-1160-x

Internet

http://link.springer.com/article/10.1186/s13058-019-1160-x

Similar Items